ANIP Q3 2019 Earnings — ANI Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

ANIPANI Pharmaceuticals, Inc.

$2B

Q3 2019 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$51M+1.3% YoY

Gross Profit

$36M70.8% margin

Operating Income

$7M14.3% margin

Net Income

$4M7.5% margin

EPS (Diluted)

$0.32

QoQ Revenue Growth

-5.6%

Cash Flow

Operating Cash Flow

$22M

Free Cash Flow

$20M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$457M

Total Liabilities

$244M

Stockholders' Equity

$213M

Cash & Equivalents

$60M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$51M	$51M	+1.3%
Gross Profit	$36M	$35M	+3.5%
Operating Income	$7M	$10M	-27.5%
Net Income	$4M	$5M	-23.1%

Revenue Segments

Unapproved Products

$5M100%

Geographic Segments

United States

$50M97%

Canada

$1M3%